This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In late 2019 and early 2020, the world was watching and monitoring a new virus that reportedly started in Wuhan, China.1 The virus (COVID-19) was easily transmittable between humans through respiratory droplets. Scientists worked diligently to develop new antiviral strategies as the virus spread exponentially within a population and between populations around the world. At the same time, health care practitioners found themselves challenged to find the optimum therapies.2–4 A common development in hospitalized patients infected with COVID-19 during the early phase of the pandemic was the progression of respiratory distress leading to failure. Since the late 1990s, there has been an internationally accepted constellation of symptoms associated with the diagnosis of ARDS. In addition, many clinicians adopted the management protocols defined in these early landmark studies. As COVID-19–induced ARDS began to present itself in hospitals across the globe, clinical researchers began to question if COVID-19 ARDS was similar to other forms of ARDS.5
In this issue of Respiratory Care, Gregory Burns and colleagues6 examine one outcome of interest, specifically time to extubation. Secondary outcomes of interest, such as time to weaning readiness and rate of PaO2/FIO2 improvement, were also …
Correspondence: Ronald E Dechert DrPH RRT FAARC. E-mail: rdechert{at}umich.edu
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
